JP7509394B2 - 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作 - Google Patents

反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作 Download PDF

Info

Publication number
JP7509394B2
JP7509394B2 JP2018552049A JP2018552049A JP7509394B2 JP 7509394 B2 JP7509394 B2 JP 7509394B2 JP 2018552049 A JP2018552049 A JP 2018552049A JP 2018552049 A JP2018552049 A JP 2018552049A JP 7509394 B2 JP7509394 B2 JP 7509394B2
Authority
JP
Japan
Prior art keywords
protein
ran
spinocerebellar ataxia
eif3f
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515894A5 (https=
JP2019515894A (ja
Inventor
ローラ・レイナム
ファトマ・アイハン
タオ・ズー
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2019515894A publication Critical patent/JP2019515894A/ja
Publication of JP2019515894A5 publication Critical patent/JP2019515894A5/ja
Priority to JP2022047328A priority Critical patent/JP7586506B2/ja
Application granted granted Critical
Publication of JP7509394B2 publication Critical patent/JP7509394B2/ja
Priority to JP2024190590A priority patent/JP2025037864A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018552049A 2016-04-04 2017-04-04 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作 Active JP7509394B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022047328A JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作
JP2024190590A JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318200P 2016-04-04 2016-04-04
US62/318,200 2016-04-04
PCT/US2017/026020 WO2017176813A1 (en) 2016-04-04 2017-04-04 Manipulation of eif3 to modulate repeat associated non-atg (ran) translation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022047328A Division JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作

Publications (3)

Publication Number Publication Date
JP2019515894A JP2019515894A (ja) 2019-06-13
JP2019515894A5 JP2019515894A5 (https=) 2020-05-14
JP7509394B2 true JP7509394B2 (ja) 2024-07-02

Family

ID=60001473

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552049A Active JP7509394B2 (ja) 2016-04-04 2017-04-04 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作
JP2022047328A Active JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作
JP2024190590A Pending JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022047328A Active JP7586506B2 (ja) 2016-04-04 2022-03-23 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作
JP2024190590A Pending JP2025037864A (ja) 2016-04-04 2024-10-30 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作

Country Status (6)

Country Link
US (3) US10940161B2 (https=)
EP (1) EP3440100A4 (https=)
JP (3) JP7509394B2 (https=)
AU (2) AU2017246643B2 (https=)
CA (1) CA3019847A1 (https=)
WO (1) WO2017176813A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
CN109504684B (zh) * 2018-12-20 2021-07-27 山西大学 Ran基因及其dsRNA在害虫防治中的应用
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US20230018989A1 (en) * 2019-07-03 2023-01-19 Children's Medical Center Corporation Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis
EP3994159A4 (en) * 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
EP4041756A4 (en) * 2019-10-10 2023-11-01 University Of Florida Research Foundation, Incorporated RAN PROTEINS AS BIOMARKERS IN CAG/CTG EXPANSION DISORDERS
KR102272985B1 (ko) * 2019-11-20 2021-07-02 충남대학교산학협력단 Eif3b(Eukaryotic translation initiation factor 3 subunit B)를 표적으로 하는 항진균제의 스크리닝 방법

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
ATE247129T1 (de) 1995-04-11 2003-08-15 Merck & Co Inc Biologisches verfahren zur herstellung von verbindungen auf der basis der dipeptiden
CA2283379A1 (en) 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
EP1000084A4 (en) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 HUMAN SECRETED PROTEINS
US6362007B1 (en) 1997-08-29 2002-03-26 Innogenetics N.V. Methylated, SMD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
JP2004518437A (ja) 2000-10-25 2004-06-24 ディアデクサス インコーポレーテッド 肺特異的遺伝子およびタンパク質に関する組成物および方法
EP1349934A2 (en) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7393642B2 (en) 2003-07-17 2008-07-01 Chicago Community Foundation Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20090075900A1 (en) 2004-04-08 2009-03-19 Sadakazu Therapeutic agent for motor neuron disease
WO2006034278A2 (en) 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
EP1844148A2 (en) 2005-01-31 2007-10-17 University of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
WO2006133194A2 (en) * 2005-06-06 2006-12-14 Vgx Pharmaceuticals, Inc Methods for treating viral infection with oral or injectible drug solution
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
PL2082225T3 (pl) 2006-09-20 2014-06-30 Univ Belfast Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację
US20080188457A1 (en) 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20090148866A1 (en) 2007-05-18 2009-06-11 Abbott Laboratories Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase
EP2164865A2 (en) 2007-06-13 2010-03-24 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
US20090143418A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) * 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
BRPI0923761B1 (pt) 2008-12-30 2019-08-13 3M Innovative Properties Co aerossol adesivo e névoa de aerossol
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2757354A1 (en) * 2009-04-02 2010-10-07 Laura P.W. Ranum Nucleotide repeat expansion-associated polypeptides and uses thereof
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CA2762351A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance
WO2011028912A2 (en) 2009-09-03 2011-03-10 University Of Tennessee Research Foundation A biomarker for neurodegeneration in neurological disease
KR101133243B1 (ko) 2009-10-29 2012-04-06 국립암센터 암의 진단 및 치료를 위한 ｅＩＦ３ｍ의 용도
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9896729B2 (en) 2011-08-31 2018-02-20 The University Of Manchester Method for diagnosing a neurodegenerative disease
US9587014B2 (en) 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014114660A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) 2013-01-24 2016-08-10 Mayo Foundation METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP2837390A1 (en) 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
CA2990161A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
JP6508996B2 (ja) 2015-03-24 2019-05-08 東ソー株式会社 β−ＡＮＰによる心不全の検出方法
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
CN109715144A (zh) 2016-08-18 2019-05-03 奥维德医疗公司 使用双胍类治疗发育障碍的方法
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
EP3962518A1 (en) 2019-05-02 2022-03-09 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Immunogen for preventing or treating familial frontotemporal dementia (ftd) and/or amyotrophic lateral sclerosis (als)
EP3994159A4 (en) 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
WO2021061537A1 (en) 2019-09-23 2021-04-01 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
EP4041756A4 (en) 2019-10-10 2023-11-01 University Of Florida Research Foundation, Incorporated RAN PROTEINS AS BIOMARKERS IN CAG/CTG EXPANSION DISORDERS
WO2021231887A1 (en) 2020-05-15 2021-11-18 University Of Florida Research Foundation, Incorporated Compositions and methods of detection of pre-symptomatic als
EP4440560A1 (en) 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｍｏｌｅｃｕｌａｒ Ｃｅｌｌ， ２０１６， Ｖｏｌ． ６２， Ｎｏ． ２， ｐ． ３１４－３２２
Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ， ２０１４， Ｖｏｌ． ４２， Ｎｏ． １９， ｐ． １１８４９－１１８６４

Also Published As

Publication number Publication date
AU2017246643B2 (en) 2022-08-04
US20250375466A1 (en) 2025-12-11
CA3019847A1 (en) 2017-10-12
JP2022101553A (ja) 2022-07-06
US20200206255A9 (en) 2020-07-02
US10940161B2 (en) 2021-03-09
EP3440100A1 (en) 2019-02-13
AU2017246643A1 (en) 2018-11-01
US12364707B2 (en) 2025-07-22
WO2017176813A1 (en) 2017-10-12
JP2019515894A (ja) 2019-06-13
US20190142858A1 (en) 2019-05-16
AU2022252755B2 (en) 2025-04-17
JP7586506B2 (ja) 2024-11-19
EP3440100A4 (en) 2020-01-22
JP2025037864A (ja) 2025-03-18
AU2022252755A1 (en) 2022-11-03
US20210236535A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7586506B2 (ja) 反復関連非ａｔｇ（ｒａｎ）翻訳を調節するためのｅｉｆ３の操作
Jaillard et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival
EP3023496B1 (en) Compounds which modulate interleukins 17 and 23 signaling activity
JP2024525614A (ja) 筋標的化複合体および筋肉の健康に関連する遺伝子の調整のためのその使用
US10532104B2 (en) Biotin complexes for treatment and diagnosis of Alzheimer'S disease
AU2004239114A1 (en) Inhibition of the expression of huntingtin gene
US20190142860A1 (en) Nucleic acid based tia-1 inhibitors
Colini Baldeschi et al. Novel regulators of PrPC expression as potential therapeutic targets in prion diseases
US20140093494A1 (en) Alpha synuclein toxicity
EP2758077B1 (en) Compounds for use in the treatment of alzheimer's disease
JP2022516779A (ja) 二本鎖ｒｎａ及びその使用
US20240401057A1 (en) Adamts14 inhibition
US20240173426A1 (en) Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
CN118434856A (zh) Adamts14抑制
O'Loughlin Towards extracellular vesicle based gene therapy for Huntington's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220323

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220401

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220405

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220520

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240613